...
首页> 外文期刊>Therapeutic Drug Monitoring >No influence of body weight on serum levels of antidepressants.
【24h】

No influence of body weight on serum levels of antidepressants.

机译:体重对抗抑郁药血清水平没有影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Body weight may affect pharmacokinetic parameters in various ways and may therefore have a significant impact on the serum concentration of a drug at a given dose. Although patients with major depressive disorder frequently show an elevated body mass index, studies investigating the relation between body weight and serum concentration of antidepressants are lacking. This study should help to clarify the influence of body weight on the serum levels of the antidepressants amitriptyline (AMI), clomipramine (CLO), doxepine (DOX), escitalopram (ESC), and venlafaxine (VEN) in a naturalistic clinical setting. METHODS: Therapeutic drug monitoring analyses obtained in the psychiatric university hospital of Wuerzburg from patients treated with AMI (n = 171), CLO (n = 94), DOX (n = 133), ESC (n = 19), and VEN (n = 24) were retrospectively assessed. The influence of body weight on dose-corrected serum concentrations was evaluated by Spearman-Rho correlations and by comparing dose-corrected serum levels in patients with low and high body weight (first versus fourth quartile). The serum concentrations were determined by high-performance liquid chromatography methods in the therapeutic drug monitoring laboratory of the psychiatric university hospital of Wuerzburg. RESULTS: Dose-corrected serum concentrations did not significantly correlate with body weight in patients treated with AMI, CLO, DOX, ESC, or VEN. There was no significant difference in the dose-corrected serum concentrations of AMI, CLO, and DOX between patients of the first and fourth quartiles of body weight. The latter evaluation was not performed for ESC and VEN because of too small samples. CONCLUSIONS: Against the intuitive presumption of a weight dependency of dose-corrected serum concentrations, the findings suggest that there is no relevant influence of body weight on the dose-corrected serum level of several widely used antidepressants even if extreme subgroups of patients with low and high body weights are considered.
机译:背景:体重可能以各种方式影响药代动力学参数,因此可能在给定剂量下对药物的血清浓度产生重大影响。尽管患有重度抑郁症的患者经常显示出较高的体重指数,但缺乏研究体重与抗抑郁药血清浓度之间关系的研究。这项研究应有助于阐明体重对自然疗法临床环境中抗抑郁药阿米替林(AMI),氯米帕明(CLO),多西平(DOX),依西酞普兰(ESC)和文拉法辛(VEN)血清水平的影响。方法:在维尔茨堡精神病大学附属医院接受AMI(n = 171),CLO(n = 94),DOX(n = 133),ESC(n = 19)和VEN(n)治疗的患者中获得的治疗药物监测分析= 24)进行了回顾性评估。通过Spearman-Rho相关性以及比较低体重和高体重(第一四分位数与第四四分位数)患者的剂量校正后血清水平,评估了体重对剂量校正后血清浓度的影响。通过高效液相色谱法在维尔茨堡精神病大学附属医院的治疗药物监测实验室中测定血清浓度。结果:接受AMI,CLO,DOX,ESC或VEN治疗的患者的剂量校正血清浓度与体重没有显着相关。在体重的第一和第四四分位数的患者之间,AMI,CLO和DOX的剂量校正血清浓度无显着差异。由于样品太少,未对ESC和VEN进行后一评估。结论:根据直觉推定的剂量校正后血清浓度与体重的相关性,研究结果表明,体重对几种广泛使用的抗抑郁药的剂量校正后血清水平没有相关影响,即使低剂量和低剂量的极端亚组患者也是如此。高体重被认为。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号